Showing 2291-2300 of 4063 results for "".
- Visus Therapeutics to Host Its First Capital Markets Day Tomorrowhttps://modernod.com/news/visus-therapeutics-to-host-its-first-capital-markets-day-tomorrow/2479476/Visus Therapeutics will host its first Capital Markets Day for investors, analysts, and media tomorrow, August 31, 2021, from 10 am to 2 pm ET at Convene, 530 Fifth Avenue at 45th Street in New York City. During the Capital Markets Day, Ben Bergo, co-founder and chief executive
- Visus Therapeutics to Host First Capital Markets Day in New York Cityhttps://modernod.com/news/visus-therapeutics-to-host-first-capital-markets-day-in-new-york-city/2479439/Visus Therapeutics announced that the company will host its first Capital Markets Day for investors, analysts, and media on August 31, 2021, from 10 am to 2 pm ET at Convene, 530 Fifth Avenue in New York City. During the Capital Markets Day, members of Visus’ leadership team and leading ey
- CDC Calls for Masks in Schools, Hard-Hit Areas, Even if Vaccinatedhttps://modernod.com/news/cdc-calls-for-masks-in-schools-hard-hit-areas-even-if-vaccinated/2479417/The Centers for Disease Control and Prevention (CDC) once again is recommending that some Americans wear masks indoors. The agency called today for masks in K-12 school settings and in areas of the United States experiencing high or substantial SARS-CoV-2 transmission, even for the fully vaccinat
- Iveric Bio Appoints Christopher Simms as Chief Commercial Officerhttps://modernod.com/news/iveric-bio-appoints-christopher-simms-as-chief-commercial-officer/2479390/Iveric bio announced the appointment of Christopher Simms to Senior Vice President and Chief Commercial Officer, effective August 2, 2021. Mr. Simms joins Iveric Bio from Novartis, where he managed commercial operations for the U.S. Ophthalmics Franchise, launching Beovu (brolucizumab inje
- Bausch Health And Clearside Biomedical Announce FDA Filing Acceptance For Xiperehttps://modernod.com/news/bausch-health-and-clearside-biomedical-announce-fda-filing-acceptance-for-xipere/2479252/Bausch Health Companies and Bausch + Lomb, along with Clearside Biomedical, announced that the FDA has accepted the resubmitted new drug application for Xipere (triamcinolone acetonide suprachoroidal injectable suspension). FDA determined that the filing is a Class 2 resubmission and therefore as
- Novartis Terminates Three Trials of Beovu Despite Meeting Primary Endpoint of MERLIN Trialhttps://modernod.com/news/novartis-terminates-three-trials-of-beovu-despite-meeting-primary-endpoint/2479246/Novartis reported that Beovu met its primary endpoint in the phase 3 MERLIN trial, but decided to terminate the study due to higher rates of intraocular inflammation with frequent dosing intervals. Novartis reported the first interpretable year 1 results of the MERLIN trial, a 2-year study
- GenSight Biologics Announces Case Report Showing Visual Recovery after GS030 Optogenetic Treatmenthttps://modernod.com/news/gensight-biologics-announces-nature-medicine-case-report-showing-visual-recovery-after-gs030-optogenetic-treatment/2479243/GenSight Biologics announced that the journal Nature Medicine has published the first case report of partial recovery of visual function in a blind patient with late-stage retinitis pigmentosa (RP). The subject is a participant in the ongoing PIONEER phase 1/2 clinical trial of GenSight
- Eyenovia Announces Topline Results From VISION-1 Phase 3 Study of MicroLine for the Treatment of Presbyopiahttps://modernod.com/news/eyenovia-announces-positive-topline-results-from-vision-1-phase-3-clinical-study-of-microline-for-the-treatment-of-presbyopia/2479241/Eyenovia announced that its VISION-1 study evaluating the company’s proprietary pilocarpine formulation, MicroLine, for the temporary improvement of near vision in adults with presbyopia, achieved its primary endpoint. Preparations are underway for a second phase 3 registration study, VISION-2. T
- New National Eye Institute Data Shows AREDS2 Nutrient Formula Continues To Reduce The Risk Of Moderate To Advanced AMD Progressionhttps://modernod.com/news/new-national-eye-institute-data-shows-areds2-nutrient-formula-continues-to-reduce-the-risk-of-moderate-to-advanced-amd-progression/2479193/Bausch + Lomb announced new data from the National Eye Institute (NEI) 10-Year Follow-on Study Results of the Age-Related Eye Disease Study 2 (AREDS2), which reaffirms the clinical outcomes of the AREDS2 study. Based on this data, the NEI continues to recommend a specific nutrient formula to help
- Roche, Regeneron’s REGEN-COV Cuts Symptomatic COVID-19 by 81% Among Household Contactshttps://modernod.com/news/roche-regenerons-regen-cov-cuts-symptomatic-covid-19-by-81-among-household-contacts/2479071/Regeneron Pharmaceuticals and partner Roche reported positive results from a phase 3 study, showing that a subcutaneous formulation of the antibody cocktail REGEN-COV (casirivimab with imdevimab) reduced the risk and burden of COVID-19 among household contacts of SARS-CoV-2-